Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03812874RecruitingPhase 1/Phase 2
Drug after chemo-embolization for liver cancer that can’t be removed
This Phase 1/2 study tests PTX-9908 (a study drug) to see if it’s safe and effective when given after TACE, a liver-directed treatment. It may help people with liver cancer that can’t be surgically removed and who have recovered enough from their recent TACE.
New Taipei City, TaiwanAges 20 years+ - NCT03899428RecruitingPhase 2
Immune therapy versus targeted therapy for advanced liver cancer
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
Hong Kong, Hong Kong SARAges 18 years+ - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04147078RecruitingPhase 1
Personalized immune vaccine after surgery for certain cancers
This Phase 1 study tests a personalized vaccine made for you to help your immune system after you’ve had surgery or ablation for certain cancers. It’s mainly done to check safety and see how well the vaccine can work at preventing cancer from coming back.
Chengdu, SichuanAges 18–100 - NCT04204850RecruitingPhase 2
Cabozantinib for liver cancer that returns after liver transplant
This trial studies cabozantinib, a cancer medicine, for liver cancer that has come back after a liver transplant. It’s for people whose cancer can’t be cured with more surgery or local procedures, to see if the treatment can help control the disease.
Toronto, OntarioAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT04371042Recruiting
Study of liver disease and genes in people with fatty liver
This study collects information about metabolic and unexplained (cryptogenic) liver disease and looks at “omics” tests, which are lab tests that measure patterns in blood or tissue to learn what drives the disease. It may help researchers better understand fatty liver and related serious complications, like liver scarring and liver cancer.
Roma, Rome/lazio/italyAges 18 years+ - NCT04442334Recruiting
European registry for people with fatty liver
This registry collects health and lifestyle information from adults with suspected or confirmed fatty liver (NAFLD) to help researchers better understand the condition. You may be asked about diet, exercise, alcohol intake, and some liver-related tests.
AntwerpAges 18–100 - NCT04455932Recruiting
Test shorter MRI versus ultrasound for liver cancer screening
This study compares a shorter, non-contrast MRI and ultrasound to monitor for liver cancer in people with cirrhosis whose ultrasound images aren’t clear enough. It aims to see which method works better and may help you get safer, more reliable follow-up.
Camperdown, New South WalesAges 20–85 - NCT04510740Recruiting
Liver cancer registry study to improve future care
This study records information about people with liver cancer (hepatocellular or bile duct cancer) to help improve how care is planned and delivered. You may join a patient-experience part before or soon after starting your first main treatment.
Multiple SitesAges 18 years+ - NCT04525833Recruiting
Visit Tzu Chi gastroenterology clinic study
This study looks at people who have visited a Tzu Chi Hospital gastroenterology clinic. It may help researchers understand liver and other whole-body health conditions in patients who receive care there.
New Taipei CityAges 18–99 - NCT04601428RecruitingEarly Phase 1
Liver artery treatment for certain liver cancer patients
This early-phase study tests a treatment delivered through the liver’s artery for people with intermediate or limited advanced liver cancer who can’t have surgery. It aims to control the cancer after prior targeted liver treatments didn’t work or the cancer grew again.
Tainan, North Dist.Ages 18 years+ - NCT04615143RecruitingPhase 2
Tislelizumab with or without lenvatinib before liver surgery
This trial studies whether taking tislelizumab alone or with lenvatinib before surgery can shrink recurrent liver cancer and improve outcomes. It may help by treating the cancer earlier (before the tumor is removed).
Guangzhou, GuangdongAges 18–75 - NCT04745403RecruitingPhase 1
Trial of redirected HBV-targeting T cells for liver cancer
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
SingaporeAges 21–75 - NCT04745390Recruiting
Testing a tailored radiation dose plan for liver tumors
This study compares a standard radiation dose plan versus a plan that adjusts the dose based on how the tumor responds to radiation-related measurements. It aims to improve how well stereotactic body radiation therapy (SBRT) treats liver cancer while keeping side effects manageable.
London, OntarioAges 18 years+ - NCT04770207RecruitingPhase 2
Injecting a cancer drug mixture directly into tumors
This Phase 2 study tests a treatment where drug-loaded tiny beads are injected into a solid tumor, using more than one medicine. It may help people with advanced solid cancers by delivering the drugs right at the tumor site.
Guangzhou, GuangdongAges 18–99 - NCT04777942Recruiting
New liver cancer treatment plan for high-risk early-stage patients
This trial studies a treatment approach (a combination given through the liver) for people with early liver cancer that can be surgically removed but has a high chance of coming back. It may help reduce the risk of recurrence after treatment.
Guangzhou, GuangdongAges 18–75 - NCT04803318RecruitingPhase 2
Test of three targeted medicines for advanced solid tumors
This Phase 2 study tests trametinib plus everolimus plus lenvatinib in people with advanced solid tumors that have come back or cannot be treated anymore. It aims to control tumor growth and symptoms when standard options have not worked.
Guangzhou, GuangdongAges 18–85 - NCT04864054RecruitingPhase 1/Phase 2
Study T-cell therapy for advanced liver cancer
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT04933435Recruiting
Image-guided radiation plus liver procedures for non-surgical liver cancer
This trial studies a combination approach—special, image-guided radiation and liver procedures—for liver cancer patients who cannot have surgery. It may help shrink tumors while protecting liver function by using planned, targeted treatment.
Durham, North CarolinaAges 18 years+ - NCT04946773Recruiting
Deep liver testing study for cancer and non-cancer liver disease
This study looks closely at how the liver’s immune system and disease processes work in people with liver problems, including some with suspected or confirmed liver/bile duct cancer. You may also be offered a liver needle sample (FNA) if it’s safe for you.
Oxford, OxfordshireAges 18–75 - NCT04952272RecruitingPhase 1
Shots into the tumor to boost the immune system
This Phase 1 study tests an injection given directly into an advanced solid tumor to help the immune system better recognize and attack cancer. It may help people with advanced solid tumors, but the goal at this early stage is mainly to check safety and how the treatment works.
Guangzhou, GuangdongAges 18–80 - NCT04988945RecruitingPhase 2
Immunotherapy with liver tumor radiation to shrink hard-to-remove liver cancer
This Phase 2 trial tests whether combining targeted liver procedures (TACE) and high-dose radiation (SBRT) followed by two immunotherapy drugs can “downstage” hepatocellular carcinoma (HCC), meaning make it smaller/less advanced. It may help some people become better candidates for future treatment by shrinking tumors.
Hong KongAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.